Absence of FGFR3–TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration

C. Banella; M. Ginevrino; G. Catalano; E. Fabiani; G. Falconi; M. Divona; P. Curzi; P. Panetta; M. T. Voso; N. I. Noguera

doi:10.1016/j.hemonc.2020.02.005

Absence of FGFR3–TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration

C. Banella, M. Ginevrino, G. Catalano, E. Fabiani, G. Falconi, M. Divona, P. Curzi, P. Panetta, M. T. Voso, N. I. Noguera

Research output: Contribution to journal › Article › peer-review

Abstract

FGFR–TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR–TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3–TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended.

Original language	English
Journal	Hematology/ Oncology and Stem Cell Therapy
DOIs	https://doi.org/10.1016/j.hemonc.2020.02.005
Publication status	Accepted/In press - 2021

Keywords

Acute myeloid leukemia
Aneuploidy
FGFR3–TACC3
Glioblastoma
Myelodysplastic syndromes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hemonc.2020.02.005

Fingerprint Dive into the research topics of 'Absence of FGFR3–TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration'. Together they form a unique fingerprint.

Cite this

@article{9d3ac01e44074fa1928be7b7d7ad23f5,

title = "Absence of FGFR3–TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration",

abstract = "FGFR–TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR–TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3–TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended.",

keywords = "Acute myeloid leukemia, Aneuploidy, FGFR3–TACC3, Glioblastoma, Myelodysplastic syndromes",

author = "C. Banella and M. Ginevrino and G. Catalano and E. Fabiani and G. Falconi and M. Divona and P. Curzi and P. Panetta and Voso, {M. T.} and Noguera, {N. I.}",

note = "Funding Information: This work was supported by AIRC 5x1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid Neoplasms Research Venture Airc, a detailed description of the MYNERVA project is available at http://www.progettoagimm.it.) and by PRIN 2017WXR7ZT_004 . Publisher Copyright: {\textcopyright} 2020 King Faisal Specialist Hospital & Research Centre Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2021",

doi = "10.1016/j.hemonc.2020.02.005",

language = "English",

journal = "Hematology/ Oncology and Stem Cell Therapy",

issn = "1658-3876",

publisher = "King Faisal Specialist Hospital and Research Centre",

}

TY - JOUR

T1 - Absence of FGFR3–TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration

AU - Banella, C.

AU - Ginevrino, M.

AU - Catalano, G.

AU - Fabiani, E.

AU - Falconi, G.

AU - Divona, M.

AU - Curzi, P.

AU - Panetta, P.

AU - Voso, M. T.

AU - Noguera, N. I.

N1 - Funding Information: This work was supported by AIRC 5x1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid Neoplasms Research Venture Airc, a detailed description of the MYNERVA project is available at http://www.progettoagimm.it.) and by PRIN 2017WXR7ZT_004 . Publisher Copyright: © 2020 King Faisal Specialist Hospital & Research Centre Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2021

Y1 - 2021

N2 - FGFR–TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR–TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3–TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended.

AB - FGFR–TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR–TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3–TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended.

KW - Acute myeloid leukemia

KW - Aneuploidy

KW - FGFR3–TACC3

KW - Glioblastoma

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=85082087376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082087376&partnerID=8YFLogxK

U2 - 10.1016/j.hemonc.2020.02.005

DO - 10.1016/j.hemonc.2020.02.005

M3 - Article

AN - SCOPUS:85082087376

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

SN - 1658-3876

ER -